Literature DB >> 18692557

Morphological changes in spiral ganglion cells after intracochlear application of brain-derived neurotrophic factor in deafened guinea pigs.

Martijn J H Agterberg1, Huib Versnel, John C M J de Groot, Guido F Smoorenburg, Frans W J Albers, Sjaak F L Klis.   

Abstract

When guinea pigs are deafened with ototoxic drugs spiral ganglion cells (SGCs) degenerate progressively. Application of neurotrophins can prevent this process. Morphological changes of rescued SGCs have not been quantitatively determined yet. It might be that SGCs treated with neurotrophins are more vulnerable than SGCs in cochleae of normal-hearing guinea pigs. Therefore, the mitochondria and myelinisation of type-I SGCs were studied and the perikaryal area, cell circularity and electron density were determined. Guinea pigs were deafened with a subcutaneous injection of kanamycin followed by intravenous infusion of furosemide. Brain-derived neurotrophic factor (BDNF) delivery was started two weeks after the deafening procedure and continued for four weeks. Four cohorts of cochleae were studied: (1) cochleae of normal-hearing guinea pigs; (2) of guinea pigs two weeks after deafening; (3) six weeks after deafening; (4) cochleae treated with BDNF after deafening. The deafening procedure resulted in a progressive loss of SGCs. Six weeks after deafening the size of mitochondria, perikaryal area and cell circularity of the remaining untreated SGCs were decreased and the number of layers of the myelin sheath was reduced. In the basal part of the cochlea BDNF treatment rescued SGCs from degeneration. SGCs treated with BDNF were larger than SGCs in normal-hearing guinea pigs, whereas circularity had normal values and electron density was unchanged. The number of layers in the myelin sheath of BDNF-treated SGCs was reduced as compared to the number of layers in the myelin sheath of SGCs in normal-hearing guinea pigs. The morphological changes of SGCs might be related to the rapid loss of SGCs that has been reported to occur after cessation of BDNF treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692557     DOI: 10.1016/j.heares.2008.07.004

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  37 in total

1.  AAV-Mediated Neurotrophin Gene Therapy Promotes Improved Survival of Cochlear Spiral Ganglion Neurons in Neonatally Deafened Cats: Comparison of AAV2-hBDNF and AAV5-hGDNF.

Authors:  Patricia A Leake; Stephen J Rebscher; Chantale Dore'; Omar Akil
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-20

2.  Comparative analysis of combination kanamycin-furosemide versus kanamycin alone in the mouse cochlea.

Authors:  Keiko Hirose; Eisuke Sato
Journal:  Hear Res       Date:  2010-10-31       Impact factor: 3.208

3.  Combining cell-based therapies and neural prostheses to promote neural survival.

Authors:  Andrew K Wise; James B Fallon; Alison J Neil; Lisa N Pettingill; Marilyn S Geaney; Stephen J Skinner; Robert K Shepherd
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

4.  Chronic neurotrophin delivery promotes ectopic neurite growth from the spiral ganglion of deafened cochleae without compromising the spatial selectivity of cochlear implants.

Authors:  Thomas G Landry; James B Fallon; Andrew K Wise; Robert K Shepherd
Journal:  J Comp Neurol       Date:  2013-08-15       Impact factor: 3.215

5.  Attenuated infrared neuron stimulation response in cochlea of deaf animals may associate with the degeneration of spiral ganglion neurons.

Authors:  Bingbin Xie; Chunfu Dai; Huawei Li
Journal:  Biomed Opt Express       Date:  2015-05-07       Impact factor: 3.732

6.  How electrically evoked compound action potentials in chronically implanted guinea pigs relate to auditory nerve health and electrode impedance.

Authors:  Kara C Schvartz-Leyzac; Deborah J Colesa; Christopher J Buswinka; Andrew M Rabah; Donald L Swiderski; Yehoash Raphael; Bryan E Pfingst
Journal:  J Acoust Soc Am       Date:  2020-12       Impact factor: 1.840

7.  Auditory-nerve responses to varied inter-phase gap and phase duration of the electric pulse stimulus as predictors for neuronal degeneration.

Authors:  Dyan Ramekers; Huib Versnel; Stefan B Strahl; Emma M Smeets; Sjaak F L Klis; Wilko Grolman
Journal:  J Assoc Res Otolaryngol       Date:  2014-01-28

8.  Connexin 26 null mice exhibit spiral ganglion degeneration that can be blocked by BDNF gene therapy.

Authors:  Yohei Takada; Lisa A Beyer; Donald L Swiderski; Aubrey L O'Neal; Diane M Prieskorn; Shaked Shivatzki; Karen B Avraham; Yehoash Raphael
Journal:  Hear Res       Date:  2013-12-12       Impact factor: 3.208

Review 9.  The use of neurotrophin therapy in the inner ear to augment cochlear implantation outcomes.

Authors:  Cameron L Budenz; Bryan E Pfingst; Yehoash Raphael
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

10.  Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs.

Authors:  Martijn J H Agterberg; Huib Versnel; Lotte M van Dijk; John C M J de Groot; Sjaak F L Klis
Journal:  J Assoc Res Otolaryngol       Date:  2009-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.